Treatment of Benign Paroxysmal Positional Vertigo with the TRV Reposition Chair

Pedersen, Mona Kyndi; Eriksen, Helle Højmark; Kjærsgaard, Jonas Bruun; Abrahamsen, Emil Riis; Hougaard, Dan Dupont

doi:10.5152/iao.2020.6320

Cited by 15 publications

(26 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In consistency with a previous MRC-1 study ( 14 ), patients who required more than ten treatments were considered treatment resistant and therefore classified as “treatment failures”.…”

Section: Methodsmentioning

confidence: 90%

“…Concomitant observation, measurement, recording of accompanying positional nystagmus and the subsequent interpretation of this important parameter is thereby optimized by videonystagmography. Finally, MRCs also allows several treatment options that are not possible by means of CRMs ( 14 ). Current MRCs include the Thomas Richard-Vitton Repositional Chair ® (MRC-1) (Interacoustics, Middelfart, Denmark), the Epley Omniax System ® (MRC-2) (Vesticon, Portland, USA), the Rotundum ® positioning chair (MRC-3) (Prolim Engineering GmbH, Küsnacht, Switzerland), and the Automated Mechanical Repositioning Treatment (MRC-4) (Byrons Medical Science & Technique Inc., Jinan, China).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Seven years of experience with treatment of benign paroxysmal positional vertigo with a mechanical rotational chair

et al. 2022

Self Cite

View full text Add to dashboard Cite

BackgroundThroughout the last decade, several mechanical rotational chairs have been developed for diagnostics and treatment of patients with a typical case history of benign paroxysmal positional vertigo. Sparse evidence, however, exists in terms of diagnostic accuracy and treatment efficiency with these mechanical rotational chairs. Also, recommendations for optimal use of these chairs are yet to be determined.ObjectivePrimary objective was to evaluate overall treatment of benign paroxysmal positional vertigo with a mechanical rotational chair and secondary objectives included description of patient- and BPPV characteristics, determination of subjective and objective outcomes, as well as analyzation of recurrence- and recurrence-related risk factors following successful treatment.MethodsRetrospective cohort study with 635 patients diagnosed with benign paroxysmal positional vertigo and treated by means of a mechanical rotational chair during a 7-year period from 2014 to 2021 at a tertiary University hospital. Patient- and disease-specific characteristics, treatment and recurrence data were collected through reviewing of patient records.ResultsThe mean number of required treatments was 2.7 when accounting for a six percent treatment failure rate (defined as a need of more than 10 treatments), and 3.7 when not. Bilateral mono-canal affection required 3.8 treatments, unilateral multi-canal 3.5 treatments, and the combination of bilateral and multi-canal affection 5.2 treatments. All these scenarios were associated with significantly higher numbers of required treatments when compared to unilateral mono-canal affection, which required 1.9 treatments. The overall recurrence rate was 25.4 percent.ConclusionA mechanical rotational chair provides successful treatment of benign paroxysmal positional vertigo. Mechanical rotational chairs should primarily be reserved for the treatment of retractable and atypical benign paroxysmal positional vertigo patients. Many aspects of the optimal use of these chairs still require elaborative assessment.

show abstract

“…In consistency with a previous MRC-1 study ( 14 ), patients who required more than ten treatments were considered treatment resistant and therefore classified as “treatment failures”.…”

Section: Methodsmentioning

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Seven years of experience with treatment of benign paroxysmal positional vertigo with a mechanical rotational chair

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…For AC-BPPV, several maneuvers including the reversed Epley's [58] and Yacovino's maneuvers [59] may be attempted [60]. A multiaxis positioning chair attached to the video-oculography may be applied for treatment of BPPV [61,62]. Modified or simplified versions of CRPs have also been proposed [63].…”

Section: Treatmentsmentioning

confidence: 99%

Update on benign paroxysmal positional vertigo

2020

View full text Add to dashboard Cite

Benign paroxysmal positional vertigo (BPPV) is the most common cause of vertigo worldwide. This review considers recent advances in the diagnosis and management of BPPV including the use of web-based technology and artificial intelligence as well as the evidence supporting the use of vitamin D supplements for patients with BPPV and subnormal serum vitamin D. Keywords Dizziness • Vertigo • Benign paroxysmal positional vertigo Hyo-Jung Kim and JaeHan Park equally contributed to this study.

show abstract

“… 10 In a recent study, Pedersen and colleagues diagnosed and treated 81 patients with refractory benign positional vertigo using the TVR Chair. 11 Successful treatment within this population was found in 92% of patients, requiring an average of 2.2 (SD, 1.7) treatments. Ultimately, these chairs do not improve the efficacy of the canalith repositioning maneuver, but they do allow repositioning maneuvers in patients who cannot easily lie down and turn the neck.…”

Section: Discussionmentioning

confidence: 86%

New Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review 2020

et al. 2021

View full text Add to dashboard Cite

Objectives To evaluate new drugs and devices relevant to otolaryngology–head and neck surgery that were approved by the US Food and Drug Administration (FDA) in 2020. Data Sources Publicly available device and therapeutic approvals from ENT (ear, nose, and throat), anesthesia, neurology (neurosurgery), and plastic and general surgery FDA committees. Review Methods Members of the American Academy of Otolaryngology–Head and Neck Surgery’s Medical Devices and Drugs Committee reviewed new therapeutics and medical devices from a query of the FDA’s device and therapeutic approvals. Two independent reviewers assessed the drug’s or device’s relevance to otolaryngology, classified to subspecialty field, with a critical review of available scientific literature. Conclusions The Medical Devices and Drugs Committee reviewed 53 new therapeutics and 1094 devices (89 ENT, 140 anesthesia, 511 plastic and general surgery, and 354 neurology) approved in 2020. Ten drugs and 17 devices were considered relevant to the otolaryngology community. Rhinology saw significant improvements around image guidance systems; indications for cochlear implantation expanded; several new monoclonal therapeutics were added to head and neck oncology’s armamentarium; and several new approvals appeared for facial plastics surgery, pediatric otolaryngology, and comprehensive otolaryngology. Implications for Practice New technologies and pharmaceuticals offer the promise of improving how we care for otolaryngology patients. However, judicious introduction of innovations into practice requires a nuanced understanding of safety, advantages, and limitations. Working knowledge of new drugs and medical devices approved for the market helps clinicians tailor patient care accordingly.

show abstract

Treatment of Benign Paroxysmal Positional Vertigo with the TRV Reposition Chair

Cited by 15 publications

References 14 publications

Seven years of experience with treatment of benign paroxysmal positional vertigo with a mechanical rotational chair

Seven years of experience with treatment of benign paroxysmal positional vertigo with a mechanical rotational chair

Update on benign paroxysmal positional vertigo

New Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review 2020

Contact Info

Product

Resources

About